Impact on Survival with Immunotherapy and Evaluation of Biomarkers in Peruvian Patients with Advanced Melanoma
Guillermo Valencia,Katia Roque,Patricia Rioja,José Huamán,Valeria Colomo,Jorge Sánchez,Cindy Calle,Raúl Mantilla,Zaida Morante,Hugo Fuentes,Tatiana Vidaurre,Silvia Neciosup,Ramon Andrade De Mello,Henry Gómez,Amaya Fernández-Díaz,Alfonso Berrocal,Carlos Castaneda
DOI: https://doi.org/10.2147/ott.s483753
IF: 4
2024-11-02
OncoTargets and Therapy
Abstract:Guillermo Valencia, 1– 3, &ast Katia Roque, 1, 4, &ast Patricia Rioja, 1– 3, &ast José Andrés Huamán, 1, &ast Valeria Colomo, 2, &ast Jorge Sánchez, 1, &ast Cindy Calle, 1, &ast Raúl Mantilla, 5, &ast Zaida Morante, 1– 3, &ast Hugo Fuentes, 1– 6, &ast Tatiana Vidaurre, 1, &ast Silvia Neciosup, 1– 3, &ast Ramon Andrade De Mello, 4, &ast Henry L Gómez, 1– 3, 7, &ast Amaya B Fernández-Díaz, 8, &ast Alfonso Berrocal, 8, &ast Carlos Castaneda 1, 2, 9, &ast 1 Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Lima, Peru; 2 Oncosalud – AUNA, Lima, Peru; 3 Grupo de Estudios Clínicos Oncológicos del Perú (GECOPERU), Lima, Peru; 4 Ninth of July University (UNINOVE), Sao Paulo, Brazil; 5 Universidad Nacional Federico Villarreal, Lima, Peru; 6 Universidad de Piura, Piura, Peru; 7 Universidad Peruana Cayetano Heredia, Lima, Peru; 8 Hospital General Universitario de Valencia, Valencia, Spain; 9 Universidad Científica del Sur, Lima, Peru &astThese authors contributed equally to this work Correspondence: Guillermo Valencia, Medical Oncology Department, Instituto Nacional de Enfermedades Neoplásicas (INEN), Angamos Este Avenue 2520, Surquillo, Lima, Peru, Tel +51 977296184, Email Introduction: Advanced malignant melanoma is a very aggressive disease, historically with poor prognosis before the new advances with immunotherapy and targeted therapies that have changed the standard of care, especially in cutaneous melanoma. Peru has aggressive features such as higher rates of acral lentiginous melanoma (ALM) subtype with historically shorter survival. Methods: This study describes Peruvian patients with advanced melanoma treated with immunotherapy (nivolumab) in two oncological institutions (public and private), including the discussion of the impact on overall survival (OS) divided by subtype (with incidence in ALM histology) and potential biomarkers that could be related to prognosis. Results: We found that immunotherapy is safe, and improves progression-free survival (PFS), OS and objective response rate (ORR) in our patients, with lower benefit in ALM histology. No prognostic blood inflammatory biomarkers were detected. Discussion: There is very limited data of Peruvian patients with metastatic melanoma treated with immunotherapy, especially the outcomes in ALM histology. Our goal is to share an example of the impact of immunotherapy in a Latin American (LATAM) population considered as an unsatisfied group with an enormous need of novel treatments and biomarkers. Keywords: advanced melanoma, immunotherapy, overall survival, biomarkers, Peru Malignant melanoma is an aggressive disease, and incidence continues to increase (ranked 5th in incidence in the United States in 2024). American Cancer Society estimates 100640 news cases (both sexes) and 8290 deaths (both sexes) in American patients with melanoma of the skin in 2024, with 4% of patients with distant metastatic disease. 1 In Peru, GLOBOCAN 2022 showed that melanoma ranked 13th in incidence (1360 new cases) and 16th in mortality (443 deaths). 2 A report of Instituto Nacional de Enfermedades Neoplásicas (INEN) (cancer center reference in Lima, Peru) mentioned that melanoma ranked 21st place in incidence (2310 new cases) with 14% patients in stage IV between years 2000–2020. 3 Outcomes in melanoma depend on the stage at presentation and other factors such as ulceration, or lactate dehydrogenase (LDH) levels, among others. Survival in patients with metastatic melanoma was historically less than 10% at 1 year, with a median progression-free survival (PFS) of 2 months and overall survival (OS) of 6 months before the use of novel systemic treatments such as immunotherapy 4–6 and target therapies. 7–9 These treatments increased OS, including a proportion of long-term responders and have changed the standard of care. Chemotherapy was historically used for treatment for advanced melanoma with limited outcomes: dacarbazine obtained a median OS of 5.6 to 7.8 months 10 and remains used especially in countries with no access to immunotherapy or targeted therapies. Melanoma is genetically heterogeneous, and includes many subtypes: cutaneous, mucosal, uveal and unknow -Abstract Truncated-
oncology,biotechnology & applied microbiology